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ABSTRACT
The human gastrointestinal tract is a complex ecosystem that harbours a rich and diverse
microflora. These microbes live in harmony with the host and exert various beneficial effects on
human health by their metabolic activities. However, in our modern life style, frequent and
indiscriminate use of antibiotics has disturbed this microbial ecosystem, resulting in occurrence
of various bowel diseases. Some live microbial food supplements can re-establish this microbial
ecosystem. Such a group of microorganisms, which positively influences the intestinal microbiota
by stimulating the growth of beneficial bacteria and suppressing the harmful ones, is collectively
known as probiotics. These have been consumed in the form of fermented milk products for
centuries. However, scientific interest in their use for health maintenance and disease prevention
has emerged over the past few years only.
Various scientific evidences show that probiotics help to reduce several disorders including
diarrhea, inflammatory bowel diseases, urinary tract infections, hypertension, allergies, and cancer.
Besides, probiotics exert several other benefits also to human beings and animals. Important
issues in the probiotic therapy include selection of appropriate strain, its viability during storage,
gut persistence potential and functional properties. Another category involved in gut health is
prebiotics. These are non-digestible food ingredients, which beneficially affect the host by
selectively stimulating the growth or activity of one or a limited number of beneficial bacteria
in the colon. This review paper highlights the major health benefits of probiotic organisms,
mechanisms of their action, criteria of selection, enumeration, and safety of their use for human
health.
 Keywords: Probiotics, prebiotics, gut microflora, microbial therapy, health modulation, microbial
ecosystem, human health, gut health
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1. INTRODUCTION
The major three components of our ecosystem,
ie, plants (producers), animals (consumers), and
microbes (degraders) have very close association
among themselves. The interaction of microbes
with animals is generally not taken in positive sense
because common man considers them as the agents
of diseases. But, this is far away from the reality.
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In an environment, microbes can interact with each
other and with animals in different ways that may
be beneficial, neutral or detrimental. Various body
parts including skin and mucosal surfaces of animals,
are colonised by a diverse group of microbes.
Most of these microbes live symbiotically with
host and cause no harm. However, sometimes, this
microbial harmony is disturbed and then some microbes
known as pathogens, adversely affect the health.
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The relationship between health and diet is
well understood as diet provides the energy and
nutrients for metabolic activities and growth. There
is an age-old quote by Hippocrates, 'Let food be
thy medicine and medicine be thy food', which
clearly indicates the importance of food for health.
However, modern medicine system has ignored the
role of food in medicine for long time. Now, efforts
are being made to understand the specific physiological
role of diet beyond the nutritional effects1.
Recently, functional food products are claimed
to promote health and wellbeing of animals including
human beings. Besides meeting the requirement of
energy, proteins, vitamins, and minerals, these food
products provide some additional benefits to body
that directly promote the state of wellbeing and
health, which further help to reduce the disease
incidences 2. Probiotics and prebiotics have occupied
the central position among such functional foods.
Probiotics have attracted attention of the nutritional
scientists for the last three decades, leading to
better understanding of their biological properties.
The word probiotic has been derived from Greek,
which means for life. The term probiotic is an
antonym to antibiotic and was coined by Lilly and
Stillwell to describe the substances produced by
one protozoan, which stimulate the growth of another3.
The concept is not new and there are many references
of microbial consumption in history. A Persian version
of the Old Testament (Genesis 18:8) states 'Abraham
owed his longevity to the consumption of sour milk'.
Probiotics have been used for centuries in the
form of substances containing Lactobacillus and
Bifidobacterium culture without specific knowledge
of their active ingredients or how these work. In
76 BC, the Roman historian Plinius recommended
the consumption of fermented milk products for
treating gastroenteritis4. Real scientific understanding
of how probiotics work began in 1907 when Metchnikoff5
introduced intoxication theory in which he stated
that major cause of ageing was toxicants formed
by intestinal putrefaction and fermentation and further
suggested that drinking beverages such as yoghurt
containing lactic acid bacteria would prevent ageing.
His observations behind this theory were based on
the belief that Bulgarian peasants lived very long
as they used to consume large quantities of soured
milk. Subsequently he isolated Bulgarian bacillus
(now Lactobacillus bulgaricus or Lactobacillus
delbrueckii) from soured milk for experimental
trials. Since then, lactobacilli suddenly attracted
world attention.
2 . DEFINITION
Probiotics have been defined in several ways,
depending upon our understanding of the mechanisms
of action of their effects on health and wellbeing
of human beings. In 1974, Parker6 defined probiotics
as organisms and substances that contribute to
intestinal microbial balance. But this definition does
not exclude antibiotics. Subsequently in 1989, Fuller7
gave a better definition of probiotics as live microbial
feed supplement, which beneficially affects the
host animal by improving its intestinal microbial
balance. This definition stressed on viability of
culture and animal as host. Later on, Havenaar8,
et al, elaborated the term as a viable mono- or
mixed culture of microorganisms which when applied
to animal or man, beneficially affects the host by
improving the properties of the indigenous microflora8.
Salminen 9, et al. further broadened the term as a
live microbial culture or cultured dairy product that
has a beneficial effect on the health and nutrition
of the host. This definition implies that probiotics
necessarily need not to be viable.
Schrezenmeir and de Vrese10 suggested that
the term nutrition might be omitted from the definition
because major effects on nutrition also imply effects
on health. Further, they suggested that the definition
should not be limited to dairy products because
other non-dairy products like sauerkraut also contain
probiotic microorganisms. Thus, they defined probiotics
as a preparation of or a product containing viable,
defined microorganisms in sufficient numbers, which
alter the microflora (by implantation or colonisation)
in a compartment of the host and by that exert
beneficial effects in this host10. This definition confines
the probiotic concept and is applicable irrespective
of the probiotic site of action and route of administration.
In 2002, Joint FAO/WHO11 Working Group on Drafting
Guidelines for the Evaluation of Probiotics in Food
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defined probiotics as live microorganisms which
when administered in adequate amounts confer a
health benefit on the host.
3 . GUT MICROFLORA
The human intestinal tract is a complex ecosystem,
which harbours a diverse and complex bacterial
community12. Gastrointestinal (GI) tract is a specialised
tube extending from the lips to anus and human
body is considered merely an outer covering of
this tube13. Gastrointestinal tract in a healthy adult
is about 30
 
long and is so complex that it is
composed of about 1014 bacterial cells, a number
that exceeds the total human body cells by a factor
of ten14. More than 75 per cent of the wet weight
of our fecal output is composed of bacterial cells
and each gram of dry weight is thought to contain
approximately 1011 microbes of about 50 different
genera belonging to over 500 different species15,16.
The most common microorganisms found in
the gut are methanogens, bacteroides, bifidobacteria,
Escherichia coli, eubacteria, Klebsiella spp.,
streptococci, lactobacilli, staphylococci, bacilli,
Fusobacterium spp., clostridia, peptococci and
peptostreptococci 17. Moreover, the bacteria in the
gastrointestinal tract are not uniformly distributed.
Stomach and duodenum harbours only 102–105 cells
of mostly facultative anaerobic bacteria like
Lactobacillus spp. and enterobacteriaceae members18.
The lower distal part of the human gut is populated




The indigenous gut microflora interacts with
each other and with human host and thus plays
important role in the health and wellbeing of the
host 19. The gut lining is primarily nourished by the
nutrients produced by these favorable bacteria20.
Our body is completely dependent upon the activities
of these bacteria for the manufacture of key vitamins,
the assimilation and distribution of nutrients, and
for the suppression of pathogenic bacteria. Probiotic
microorganisms fall mainly under two categories.
The first include those bacteria that normally inhabit
the intestinal tract, and ingestion of these bacteria
improves the intestinal microbial balance. The second
category comprise those bacteria that do not normally
colonise the intestinal tract and the effect on intestinal
microbial balance is expected to be less, eg Lactobacillus
bulgaricus, Streptococcus thermophilus, etc21
.
4 . HEALTH BENEFITS OF PROBIOTICS
There is a strong health burden on modern
society in the form of various allergic and gastrointestinal
diseases due to changed food habits and environmental
pollution. Significant immunologic and inflammatory
activation constantly prevails in the gut but there
is lack of stimuli priming for protective mechanisms,
which directs the milieu in the gut towards a propensity
to inflammatory diseases22. Dietary and microbial
antigens provide the earliest and the most significant
driving force for the development of defence mechanisms
in the gut.
In the past decade, there has been a dramatic
increase in scientific research advocating the clinical
benefits of ingesting specific non-pathogenic organisms.
Probiotics have been shown to reinforce the different
lines of gut defence, which are immune exclusion,
immune elimination, and immune regulation23. These
are intended to modify the gastrointestinal microflora
in such a way that host-favourable microbial activities
are stimulated and those adverse to host are suppressed.
A large number of microorganisms have been used
as probiotics (Table 1). These mainly act in small
intestine24. Clinical benefits of probiotics are obtained
when gut microbial ecology is disturbed by any
change in the environment or diet. Several clinical benefits
of probiotics have been found by various experimental
trials. Some of these are being described here.
4.1 Gastrointestinal Tract Infections
4.1.1 Acute Diarrhea
The best-documented clinical benefit of probiotics
is in the treatment of acute diarrhea. A variety of
probiotics organisms including Lactobacillus
rhamnosus, Lactobacillus reuteri, Saccharomyces
boulardii and Enterococcus faecium25,26 have been
used in oral rehydration for acute diarrhea. Some
probiotic bacteria have been found to increase the
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level of IgA concentration against rotavirus in children
serum27.
4.1.2 Traveler's Diarrhea
This is the most common health problem of
travelers to tropical countries affecting 15-56 per
cent travelers28. This is caused by ingestion of
pathogens like enterotoxigenic Escherichia coli,
Giardia and Entamoeba histolytica through food
or water that overcome the protective effects of
the normal intestinal flora29. Theoretically, traveler's
diarrhea can be prevented simply by the principle
of cook it, boil it, peel it, or avoid it but practically
it a very difficult. Many antibiotics are able to
prevent diarrhea for a short period of time but
these are associated with other adverse effects.
Prophylactic ingestion of probiotics could decrease
the risk of disease30. However, the reported
benef i ts of prophylact ic probiot ics l ike
Saccharomyces boulardii, Enterococcus faecium,
Lactobacillus rhamnosus for traveler's diarrhea
have been found modest30.
4.1.3 Antibiotic-associated Diarrhea
Antibiotic-associated diarrhea or antimicrobial-
associated diarrhea is the most common adverse
effect of antibiotic therapy31
. This is supposed to
be due to perturbation of the balance of the normal
intestinal flora due to which opportunistic microorganisms
overgrow and cause diarrhea30. Clostridium difficile
is the major agent involved in Antibiotic-associated
diarrhea and colitis32. Recent studies have shown
that selected probiotics agents like Lactobacillus
acidophilus, Lactobacillus bulgaricus, Lactobacillus
rhamnosus, Bifidobacterium longum and Enterococcus
faecium have potential to prevent Antibiotic-associated
diarrhea30. Another biotherapeutic agent, non-pathogenic
yeast, Saccharomyces boulardii that grows optimally
at body temperature has also been used to cure Antibiotic-
associated diarrhea33.
4.1.4 Acute Infantile Diarrhea
Acute infantile diarrhea is a persistent problem
in developing countries that can be addressed by
inexpensive probiotics. Saavedra34, et al. evaluated
an infant formula supplement having Bifidobacterium
bifidum and Streptococcus thermophilus versus
the un-supplemented formula in preventing the diarrhea
in hospitalised infant population over a period of
17 months34. They found that supplemented formula
significantly reduces the risk of diarrhea and shedding
of rotavirus.
Lactobacillus spp. Bifidobacterium spp. Enterococcus spp. Other spp. 
L. bulgaricus B. bifidum E. faecalis Eischerichia  coli 
L. delbrueckii B. longum E. faecium Bacillus cereus 
L. acidophulus B. infantis E. avium Pediococcus acidilactici 
L. casei B. pseudolongum  Pediococcus pentosaceus 
L. plantarum B. breve  Propionibacterium freudenreichii 
L. fermentum B. thermophilum Leuconostoc spp. Saccharomyces cerevisiae 
L. lactis B. eriksonii L. lactis Saccharomyces boulardii 
L. helveticus B. animalis L. mesenteroides Streptococcus thermophilus 
L. cremaris B. adolescentis L. citreum Sprolactobacillus inulinus 
L. leichmanni  L. paramesenteroides  
L. paracasei  L. pseudomesenteroides  
L. gasseri    
L. reuteri    
L. rhamnosus    
L. salivarius    
L. amylovorus    
L. johnsonii    
 
Table 1. List of important probiotic organisms used for health modulation
517
GOEL, et al.: PROBIOTICS: THE MICROBIAL THERAPY FOR HEALTH MODULATION
4.2 Urinary Tract Infections
Urinary tract infections is a very common problem
in women that usually occurs when bacteria enter
the opening of the urethra and multiply in the
urinary tract. Escherichia coli is one of the major
pathogens responsible for urinary tract infections35.
Other bacteria that cause urinary tract infections
include Proteus, Klebsiella, Citrobacter,
Enterobacter, Pseudomonas spp, Staphylococcus
saprophyticus, Chlamydia trachomatis, and
Mycoplasma hominis 36,37.
These pathogens can be replenished with probiotics
organisms through vaginal application. The probiotics
strains for use in urinary tract infections should be
highly adherent and inhibitory to pathogens30,38.
Besides, a healthy vaginal tract harbours a high
population of lactobacilli 39. This fact, coupled with
the intestinal route of transmission of bacteria to
the urogenital tract has led to the theory that oral
probiotics may be useful in treatment or prevention
of urinary tract infections in women. Probiotic
therapy has been shown to be safe and evidences
show that this harnesses the potential to make an
input in women's health.
4.3 Bacterial Vaginosis
Vagina is naturally colonised by Lactobacillus
bacteria, which acidify the vaginal environment
and suppress the growth of other organisms. Sometimes
this normal vaginal flora is disturbed due to which
some other, less benevolent organisms including
Prevotella bivia, Prevotella. disiens, Porphyromonas
species, Mobiluncus species, Peptostreptococcus
species, Gardnerella vaginalis and Mycoplasma
hominis overpopulate and causes bacterial vaginosis36,40.
Complications arising from bacterial vaginosis
include increased risk of sexually-transmitted diseases
including human immunodeficiency virus (HIV) and
elevated risk of pre-term birth41. Probiotics have
been proposed as an effective and alternative tool
to antibiotics for treatment of bacterial vaginosis42,43.
4.4 Inflammatory Bowel Disease
Inflammatory bowel disease results when cells
involved in inflammation and immune response enter
into Gastrointestinal tract lining. Inflammatory bowel
disease mainly covers two diseases - Crohn's disease,
which may develop in any part of Gastrointestinal
tract and ulcerative colitis that occurs mainly in
large intestine. Intestinal microflora plays a key
role in the development of the inflammatory bowel
disease resulting in the clinical conditions of Crohn's
disease and ulcerative colitis44,45
. Inflammatory bowel
disease is characterised by a chronic dysregulation
of the inflammatory response in the gastrointestinal
tract where the number of adherent and pathogenic
bacteria is high46.
Immunomodulators and antibiotics have not
been found much effective in a large proportion
of patients with inflammatory bowel disease. Therefore,
a potential approach to treat or prevent inflammatory
bowel disease could be changing the microflora
to a more benign nature. Hence, probiotics have
enormous potential in treatment of such diseases
as these favourably modulate the host intestinal
flora. Animal models of colitis have provided the
proof of principle that probiotics can prevent and
treat the established intestinal inflammation47,48.
Floch 49 has reported the success of using Escherichia
coli Nissle strain alone and a multiple organism
product in treatment of ulcerative colitis and Crohn's
disease, respectively.
4.5 Atopic Eczema
The incidences of allergic diseases are increasing
day by day all over the world. Probiotics have
potential to reduce such instances, especially in
atopic eczema. This is an allergic disease in which
there is tendency for excess inflammation in the
skin and lining of nose and lungs. Atopic eczema
is very common in all parts of the world. It can
occur at any stage in the life of a human being but
is most common in infants. In a study, perinatal
administration of the probiotic Lactobacillus rhamnosus
strain GG reduced incidence of atopic eczema in
at-risk children during the first two years of life50.
In another study, supplementation of infant formulas
with viable lactobacilli helped in the management
of atopic eczema and cow's milk allergy51. Similarly,
Bifidobacterium lactis modified the changes related
to allergic inflammation in infants52.
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4.6 Blood Cholesterol and Hypertension
Cholesterol is the principal body sterol present
in all the tissues. This becomes the precursor of
all other steroids in the body. Mainly, cholesterol
is synthesised in liver, gut, and skin53. Its synthesis
and absorption occurs in the intestine. Therefore,
intestinal microflora could have profound effects
on the lipid metabolism54,55. As probiotics modify
the intestinal microflora, these may potentially reduce
the risk of heart disease by lowering blood cholesterol
levels, increasing resistance of low-density lipoprotein
(LDL) cholesterol to oxidation, and reducing blood
pressure56. Numerous studies have demonstrated
that bcsteria like Lactobacillus acidophilus,
Bifidobacterium bifidum, and Lactobacillus
bulgaricus lower cholesterol in a significant way
when its level is too high57.
The negative effects of hypertension on human
health are well known. In some cases, probiotics
have been found useful in controlling hypertension58.
The anti-hypertension activities are supposed due
to cell wall fragments of probiotic bacteria59 or
production of bioactive peptides from milk60.
4.7 Carcinogenesis
Colon cancer is one of the major causes of
cancer morbidity and mortality. Probiotics have
been found useful in prevention of colon cancer.
Clinical studies have shown that consumption of
Lactobacillus casei delayed the recurrence of bladder
tumours 61. Similarly, dietary administration of
Bifidobacterium longum in laboratory animals
significantly inhibited the incidences of colon
adenocarcinomas and colon tumor multiplicity62. In
another study on animals, Bifidobacterium longum
inhibited the mammary and liver carcinogenesis,
which indicated that anticarcinogenic activity of
probiotics may extend beyond the intestinal tract63.
Femia 64 et al. reported the use of Lactobacillus
rhamnose and Bifidobacterium lactis in protection
of rats against azoxymethane induced colon cancer.
5 MECHANISMS OF ACTION OF
PROBIOTICS
The mechanisms, by which the probiotics act,
are not yet fully understood. A common belief how
probiotics work is that ingestion improves the balance
of intestinal microflora due to which pathogen growth
is restricted30
. But this concept is a simplistic and
probiotics seem to work by multiple mechanisms.
Gut microflora plays an important role in the intestine's
defence barrier. Many gastrointestinal dysfunctions
are based on disturbances or imbalance of intestinal
microflora9. When microbial balance is disturbed
in the intestine, antigen transport is increased, leading
to increased allergic sensitivity67. There are several
factors, which can disturb the delicate balance of
microflora in the gastrointestinal tract. Some of
these include overgrowth of undesirable microorganisms,
poor hygiene, too many sweets, starchy foods or
alcoholic beverages, food allergies, frequent use of
antibiotics, exposure of radiations, surgical complications,
excessive stress, and environmental toxins.
Various beneficial microorganisms produce essential
nutrients through fermentation in the intestine. These
include vitamins, short-chain fatty acids, (without
which cell may be damaged, leading to a loss of
function in the gut lining). Probiotics include viable
as well as non-viable cell cultures that lead to
better human health by various mechanisms. Some
of the postulated mechanisms are discussed here.
5.1 Production of Antimicrobial Substances
 Antimicrobial compound production is considered
as the most important mechanism by which probiotics
act. These compounds suppress the growth of potentially
harmful microbes that reside in the human intestinal
tract. Probiotic bacteria secrete a large number of
anti-microbial compounds, which include organic
acids (lactic acid and acetic acid), hydrogen peroxide
(in aerobic environment), ß-hydroxypropionaldehyde
and bacteriocins68,69. Bacteriocins are low molecular
weight microbial compounds, which restrict the
growth of similar or related bacteria70,71. The intestinal
growth of all other kinds of non-intestinal pathogens
is strongly inhibited by abundant probiotics fermentation
in the small bowel because available sugars are
easily fermented to lactic acid and/or ethanol72.
Viral infectivity is also reduced by probiotics due
to ethanol or acid-mediated denaturation of viral
envelope proteins. Therefore, pathogens do not
overpopulate when sufficient number of probiotic
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organisms are present. Thus, objective of probiotic
therapy is to restore colonisation resistance until
the normal microbial flora becomes re-established.
5.2 Competition of Pathogens for Adhesion
Receptors
When the number of probiotic bacteria is more
in intestine, pathogens have to compete with these
beneficial bacteria for nutrient and space. Moreover,
pathogens also compete with probiotic strains for
adhesion receptors in which they rarely get success.
Thus in this race, probiotics microorganisms resist
the establishment of pathogens by competition for
food and establishment.
5.3 Production of Digestive Enzymes
Probiotics produce certain digestive enzymes
or influence enzyme activity in the gastrointestinal
tract, which may account for some of their physiologic
effects73. In a study, probiotics effect was investigated
on the development of carbohydrase and peptidase
activity in the mucosa at five sites along the small
intestine of pigs. Probiotic extended a significant
effect on the development of sucrase (EC 3.2.1.48),
lactase (EC 3.2.1.23) and tripeptidase (EC 3.4.11.4)
activities74. When the concentration of lactose cleaving-
enzyme, ie -galactosidase is too small in the brush
border membrane of the mucosa of the small intestine,
it results in lactose intolerance. Probiotics and
fermented milk products help in lactose digestion
because active microbial  -galactosidase in bacteria
survives gastric passage and is released by bile
salts into the small intestine, where it supports
lactose digestion75. Thus, probiotic organisms help
in digestion process by secreting various digestive
enzymes that help foods to breakdown.
5.4 Production of Short-chain Fatty Acids
In the colon, short-chain fatty acids (SCFAs),
such as acetic acid, propionic acid, and butyric
acid are essentially produced by the anaerobic
fermentation of carbohydrates, including dietary
fibre, resistant starch, and mucus. These short-
chain fatty acids exert a variety of physiologic
effects76. Research studies have suggested that
short-chain fatty acids exert a therapeutic effect
on some human beings and experimental animal
diseases77
. Relative efficacy of short-chain fatty
acids production was found to differ between intestinal
microflora, ie, bifidobacteria, lactobacilli, bacteroidaseae,
clostridia, and eubacteria78.
Out of these bacteria, Clostridium butyricum
was having high capability to produce n-butyric
acid. Besides, short-chain fatty acids become the
preferential fuel for mucosa cells and short-chain
fatty acids, such as lactic acid, provide up to 70
per cent of the energy required by intestinal epithelial
cells79. These make intestinal pH more acidic due
to which intestinal pathogens do not overgrow and
their population is kept in check. Lower intestinal
pH facilitates absorption of minerals such as calcium,
magnesium, and zinc80. Short-chain fatty acids have
been reported to have theraupeutic potential in
inflammatory bowel disease, ulcerative diseases,
various allergic diseases, and even in cancer76.
5.5 Stimulation of Immune System
Probiotic organisms modulate the host immunity
functions by enhancing both the cell-mediated and
humoral immune systems81. It has been well estasblished
that germ-free animals have underdeveloped immune
system that can be easily restored upon the introduction
of even a single bacterial species82. Even, microbial
imbalance in the gut leads to exacerbated effector
response and chronic inflammatory diseases. It
has been found that probiotic organisms increase
numbers of circulating white blood cells, stimulate
phagocytosis, and elevate levels of antigen-specific
antibodies.
Experiments with laboratory animals have shown
that lactobacilli increase the proportions of CD25+
cells in the lamina propria83 and decrease the T
cell reactivity84,85. Probiotic organising have been
reported to modulate the host's immune responses
to potentially harmless antigens by prompting down-
regulation of hypersensitivity reactions86. One study
correlated the low levels of lactobacilli in the vaginal
tract with increased incidence of HIV-1 in younger
women, which proved the importance of maintaining
healthy flora to ensure proper immune function87.
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5.6 Reduction in Food Allergy
Food allergies are caused by the body's sensitivity
to certain foods. On the basis of epidemiological
studies, it has been hypothesised that stimulation
of the immune system by certain microbial products
may prevent or treat allergic diseases88. Probiotics
have been proven effective in food allergy89 and
allergic inflammation52. Probiotics promote potentially
antiallergenic processes like T-helper1 type immunity88,
induce oral tolerance90 and IgA production91. Probiotic
bacteria have been reported to promote endogenous
barrier mechanisms in patients with atopic dermatitis
and food allergy88. Kalliomäki92 et al. found that
gut microflora has unique, yet largely unexplored,
endogenous immunomodulatory properties indispensable
in the fight against the increasing frequency of
atopic, and possibly other immunological diseases.
5.7 Anticarcinogenic Activity
Probiotics have been found to inhibit some
cancer-causing fecal bacterial enzymes. Lactobacilli
do not produce enzymes like nitrate reductase,
azoreductase, 7- -dehydroxylase and tryptofanase,
which are involved in the biosynthesis of mutagenous
compounds72. Besides, they suppress the growth
of other intestinal bacteria that convert pre-carcinogens
into carcinogens. Consumption of probiotics resulted
in decreased activity of ß-glucoronidase, nitroreductase,
and choloylglycine hydrolase93. Sometimes, probiotic
strains bind to mutagenic compounds in intestine
and thus reduce the absorption of mutagen from
the intestine94. Thus, they play important role in
preventing the small bowel carcinogenesis.
5.8 Inhibition of Bacterial Translocation
Bacterial translocation and subsequent sepsis
is a problem in immuno-compromised patients, where
intestinal bacteria pass across the intestinal wall
and reach extraintestinal sites. Several facultative
anaerobes like Escherichia coli, Klebsiella pneumonia,
and Proteus mirabilis can translocate to mesenteric
lymph nodes95. Probiotics exert inhibitory effects
on bacterial translocation. Probiotic bacterium
Lactobacillus casei inhibited the bacterial translocation
of Escherichia coli in a dose-dependent manner
in an in vitro cell culture model96.
5.9 Lowering of Serum Cholesterol
Probiotics can improve the health in human
beings by lowering the serum cholesterol. This has
been hypothesized from the fact that bacteria can
remove cholesterol from culture media97
. Several
strains including Lactobacillus acidophilus,
Lactobacillus gasseri, Enterococcus faecium,
Streptococcus thermophilus have been found to
lower serum cholesterol in different studies81. Now
it has been established that cholesterol is removed
from the culture media by precipitation with free
bile acids, formed in the culture media due to activity
of bacterial enzyme bile salt hydrolase98.
6. SELECTION OF PROBIOTIC STRAIN
The selection of health-promoting probiotic agents
has been an apparent problem since the time of
Metchnikoff, who first proposed the therapeutic
use of these bacteria. Commercial products do not
always specify the strain of microorganisms they
contain. Most of the ingested bacteria are killed in
the stomach. Only a small number of strains colonise
the human gastrointestinal tract. Such strains are
known as implantable strains. Implantation is thought
to be the most important criteria of a probiotics
strain to harness its full potential.
In the last decade, scientists have arrived on
a consensus on some criteria like ecological origin
of bacteria, their tolerance to the hostile conditions
of stomach and small intestine, and their ability to
adhere to intestinal surfaces65. Several criteria have
been defined that consider a microorganism as a
probiotic24,66 agent. According to these criteria, a
probiotic microorganism should be of human origin,
demonstrate non-pathogenic behaviour, should be
beneficial to host animal in some way, exhibit resistance
to technological processes, prove resistant to gastric
acid and bile, adhere to gut epithelial tissues, be
able to persist in the gastrointestinal tract, produce
anti-microbial substances, modulate immune responses,
and should have the ability to influence metabolic
activities. Besides all these factors, stability of a
probiotic strain is also equally important. Commercially
available dried formats of probiotic strains should
be stable over a longer period of time at room
temperature.
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There are several techniques developed for
detection and enumeration of probiotic organisms
in bio-products. Most of these techniques are based
on oxygen tolerance, nutritional requirement, antibiotic
susceptibility, and colony morphology99. However,
phenotypic analysis of bacteria depends upon culture,
which makes identification of these organisms a
difficult procedure.
Recently, a number of molecular methods have
been introduced for detection and enumeration of
these bacteria. Systematic bacteriology has undergone
a revolution with the advent of 16S ribosomal RNA
sequence analyses100. The major advantage of these
molecular methods is that there is no need of
cultivation of microorganisms and the methods are
universally applicable. These are helpful, especially
for detection of gastrointestinal tract organisms
most of which are strict anaerobes.
Most of these methods use sequence analysis
of ribosomal DNA (r DNA). 16S  r DNA gene
from the sample is amplified with polymerase chain
reaction (PCR) using primers against universally
conserved regions of the gene. The PCR products
are directly sequenced and compared to the r DNA
database101. Plasmid profiling is also done for the
characterisation of probiotic strains. However, this
is not very much reproducible because of the instability
of extra-chromosomal DNA102.
Other techniques include restriction enzyme
analysis (REA), pulse field gel electrophoresis (PFGE)
and random amplified polymorphic DNA (RAPD).
In REA, chromosomal DNA is digested with restriction
enzymes and fragments are separated on agarose
gel and banding pattern is visualised using computer-
aided programme. This technique has been used
successfully in differentiation of various probiotic
bacteria103-105. In PFGE, the orientation of electric
field is changed periodically and rare cutting enzymes
are used. Therefore, less number of fragments is
obtained due to which banding pattern comes very
clear. RAPD is a PCR-based technique in which
short random primers are used for amplification of
randomly-sized DNA fragments.
Microorganisms can also be monitored directly
by fluorescent in situ hybridisation (FISH). In this
technique, fluorescent probes are prepared by end
labelling of r RNA-targeted oligonucleotides with
fluorescent dye. Being small in size, these probes
penetrate the whole fixed cells and hybridize to
intracellular r RNA106
. In several cases, probiotics
organisms are monitored in gastro intestinal tract
by tagging the organisms with reporter genes, viz.,
luciferase gene of Vibrio harveyi and green fluorescent
protein (gfp) gene of Aqueria victoria107.
7 . SAFETY OF PROBIOTICS
Safety of probiotics is of utmost importance
as these are the component of food stuffs or drugs.
Many of the probiotics strains like Lactobacillus
species have been used since ancient times, and
until now, the safety of these microbes has not
been questioned 108. Therefore, members of some
genera like Lactobacillus and Lactococcus have
acquired the status of generally recognised as safe
(GRAS)109.
Generally, microorganisms can be divided into
three groups, non-pathogens, opportunistic pathogens,
and pathogens9. Sometimes, non-pathogenic microbes,
which survive within the host, can cause infection
under certain circumstances, like in severely immuno-
compromised hosts. In a few cases, lactic acid
bacteria, which are used as probiotics, have been
isolated from local or systemic infections, including
septicemia, meningitis, and endocarditis110,118. However,
such reports are scanty. A Lactobacillus rhamnosus
strain indistinguishable from Lactobacillus rhamnosus
GG was isolated from a liver abscess from an
elderly lady with a history of hypertension and
diabetes mellitus. In another case a probiotic
Lactobacillus rhamnosus strain was supposed to
cause endocarditis in an elderly male110. These
findings indicate that although probiotic products
have been consumed safely, over the years, occasional
severe infections may occur in immuno-compromised
patients.
Nowadays, new probiotic strains having more
beneficial effects are being developed. Therefore,
it becomes essential to ensure their safety. Safety
aspects include specifications such as origin, non-
pathogenicity, toxicity and antibiotic resistance
characteristics 111. The absence of pathogenicity
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and infectivity is a requisite of probiotics bacteria108.
However, it is very difficult to prove the infectivity
of probiotic bacteria. The safety of a bacterial
strain may be evaluated by considering questions
such as whether bacterial invasion of the host
leads to infection, whether infection results in severe
outcome, and the effect of association of the bacteria
with the host. Viable and non-viable cells of
Lactobacillus rhamnose, Lactobacillus acidophilus
and Bifidobacterium lactis promoted the growth
of young Swiss mice ensuring the safety of these
strains 112. Similarly, Propionibacterium jensenii
survived in vivo gastrointestinal tract of rats with
no adverse affect on the animal113.
Second important requisite of probiotics is that
they should not produce harmful or toxic substances
by metabolic activities. In the intestine, ammonia,
indole-phenol and amines are produced from the
digestion of proteins114. Probiotic bacteria have
lower deaminase activity involved in the production
of ammonia from amino acids and higher ammonia
assimilation activity than the other intestinal bacteria115.
Moreover, probiotics bacteria have been found to
lack 7- -dehydrogensae activity, which is involed
in the production of secondary bile acids116.
Antibiotic resistance of probiotics organisms is
also important. Many probiotics microbes have acquired
antibiotic resistance by contact with antibiotics or
through transformation117. But there is no report of
transfer of antibiotic resistance during therapy30.
Recently, Asahara,118 et al. suggested that resistance
to host innate defence systems should be considered
in the safety assessment of probiotic strains.
8 . PREBIOTICS
Sometimes, some food components are not
completely degraded in the stomach. These are
pass to large bowel where specific group of
microorganisms utilises these. Such substances that
escape digestion in the upper gut, enter the colon
and preferentially enhance the growth of non-pathogenic
intestinal bacteria, are known as prebiotics24. These
food gradients are neither hydrolysed nor absorbed
in the upper gastrointestinal tract. These become
substrate for the beneficial microorganisms and
induce the systemic beneficial effects for the health
of the host. Several substances including inulin,
fructo oligosaccharides (FOS), xylo-oligosaccharides,
galacto-oligosaccharides and isomalto-oligosaccharides,
lactulose, etc. fall in this category119
.
Prebiotic research is in its infancy stage and
there are scanty reports of clinical trials showing
their efficacy. However, preliminary studies are
encouraging, which indicate that these possess high
potential to influence human health. These have
been found useful in alleviation of constipation,
treatment of hepatic encephalopathy, improvement
of bioavalibility of minerals, and production of short-
chain fatty acids24,120.
9 . CONCLUSION
Probiotics and prebiotics are the microbial drugs
that harness the potential of human health modulation.
These form a component of our food system since
the ancient times in the form of fermented foods.
But, over the past few years, these have been
commercialised by in vitro culturing. Therefore,
probiotics is an old recipe, which is being used now
in functional foods. These have been found to give
a number of clinical and physiological benefits on
human health. The exact mechanisms of their working
are not clear, but under the right conditions, these
protect the body by suppressing the growth of
intestinal and some other mucosal surface pathogens.
Selection of these organisms is critical, which
is mainly based upon their origin, gut colonisation
potential, and viability under storage conditions.
Most of probiotics have been found safe but safety
assessment of recently discovered and recombinant
probiotic strains is of utmost importance. Thus,
probiotics could be the cost effective drugs for the
third world countries. Future research for better
understanding of the interaction of probiotic strains
with gut or vagina by genomics and proteomics
approaches is required. Further, unraveling the exact
mechanisms of their action, probiotics could be
used for specific health benefits.
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